Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Lenalidomide clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Lenalidomide as a study intervention. Browse Lenalidomide recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
703
Shown on this page
12
Current sort
Recently updated
Therapy scope
Lenalidomide
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Lenalidomide. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 145–156 of 703 matching trials for Lenalidomide.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Completed Phase 1 Interventional

Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

NCT01838434
View directory record Official record
Conditions
Relapsed/Refractory Mantle Cell Lymphoma
Interventions
lenalidomide, idelalisib
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
4
States / cities
Chicago, Illinois • St Louis, Missouri • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 23, 2026, 8:10 PM EDT
Completed Phase 2 Interventional Results available

Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting

NCT01946477
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Pomalidomide, Dexamethasone, Daratumumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
33
States / cities
Tucson, Arizona • Greenbrae, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 23, 2026, 8:10 PM EDT
Completed Phase 3 Interventional Results available

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma

NCT03570892
View directory record Official record
Conditions
Non-Hodgkin Lymphoma
Interventions
Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy, Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
22
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 23, 2026, 8:10 PM EDT
Completed Phase 2 Interventional Results available

Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

NCT02232516
View directory record Official record
Conditions
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Peripheral T-cell Lymphoma, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IA Mycosis Fungoides/Sezary Syndrome, Stage IB Mycosis Fungoides/Sezary Syndrome, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIA Mycosis Fungoides/Sezary Syndrome, Stage IIB Mycosis Fungoides/Sezary Syndrome, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIIA Mycosis Fungoides/Sezary Syndrome, Stage IIIB Mycosis Fungoides/Sezary Syndrome, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IVA Mycosis Fungoides/Sezary Syndrome, Stage IVB Mycosis Fungoides/Sezary Syndrome
Interventions
romidepsin, lenalidomide, laboratory biomarker analysis
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
5
States / cities
Duarte, California • New Haven, Connecticut • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 23, 2026, 8:10 PM EDT
Completed Phase 2 Interventional

MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients

NCT04032626
View directory record Official record
Conditions
Cognitive Impairment, Mild, Cognitive Dysfunction, Amyloid Plaque, Neurodegeneration, Inflammation, Brain
Interventions
Lenalidomide 10 mg, Placebo
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
50 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Phoenix, Arizona • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 23, 2026, 8:10 PM EDT
Recruiting Phase 3 Interventional

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

NCT05561387
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Lenalidomide, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
397
States / cities
Anchorage, Alaska • Phoenix, Arizona • Fort Smith, Arkansas + 287 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 23, 2026, 8:10 PM EDT
Withdrawn Phase 2 Interventional

Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

NCT06348147
View directory record Official record
Conditions
Newly Diagnosed Multiple Myeloma, Multiple Myeloma, Autologous Stem Cell Transplantation
Interventions
Daratumumab, Lenalidomide, Bortezomib, Dexamethasone
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 23, 2026, 8:10 PM EDT
Recruiting Phase 2 Interventional

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

NCT06974786
View directory record Official record
Conditions
Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)
Interventions
Elranatamab, Daratumumab, Lenalidomide, autologous stem cell transplantation
Drug · Procedure
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
19 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
11
States / cities
Birmingham, Alabama • Denver, Colorado • Iowa City, Iowa + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 23, 2026, 8:10 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

NCT01415752
View directory record Official record
Conditions
Lymphoma, Mantle Cell Lymphoma
Interventions
rituximab, Bendamustine, bortezomib, lenalidomide
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2031
U.S. locations
416
States / cities
Anchorage, Alaska • Antioch, California • Fremont, California + 283 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 23, 2026, 8:10 PM EDT
Recruiting Phase 2 Interventional

Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

NCT05145400
View directory record Official record
Conditions
Multiple Myeloma, Cancer
Interventions
Isatuximab, Lenalidomide, Dexamethasone
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
5
States / cities
Chapel Hill, North Carolina • Charlotte, North Carolina • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 23, 2026, 8:10 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

NCT03652064
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab, Bortezomib, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
19
States / cities
Cerritos, California • Jacksonville, Florida • Fort Wayne, Indiana + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 23, 2026, 8:10 PM EDT
Active, not recruiting Phase 1 Interventional

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

NCT04739813
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma
Interventions
obinutuzumab, prednisone, Revlimid, Polatuzumab, ibrutinib, venetoclax
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 23, 2026, 8:10 PM EDT

About this Lenalidomide clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Lenalidomide as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Lenalidomide.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Lenalidomide.